Trial reportEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2024
Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies.
Trial report in Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04893317 (Cryoablation for Monomorphic Ventricular Tachycardia), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cryoablation for Monomorphic Ventricular Tachycardia
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Heterogeneity of outcomes reporting in catheter ablation trials for ventricular tachycardia: a systematic review.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Pooled it
- Disappearance of local ventricular components during extrastimulus pacing after ultra-low-temperature cryoablation for ventricular tachycardia: a case report.European heart journal. Case reports · 2026Article
- Combined Endocardial Pulsed Field: Radiofrequency Ablation of a 3-Dimensional Ventricular Tachycardia With MidMyocardial Isthmus.JACC. Case reports · 2026Article
- Advances in Catheter Ablation of Ventricular Tachycardia: Technical Considerations and Contemporary Approaches.Reviews in cardiovascular medicine · 2026Review
- Advancements in mapping, cardiac imaging, and ablation techniques for the management of ventricular tachycardias.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2026Review
- Three-Dimensional Perspective on Scar-Related Ventricular Tachycardia Substrate: Critical Conduction Abnormalities as Ablation Targets and Implications for Procedural Endpoints.Reviews in cardiovascular medicine · 2026Review
- "From Surface to Substrate: Advancing VT Ablation Strategies for Deep Arrhythmic Substrates"-A Review of Emerging Techniques in Intramural Lesion Formation.Reviews in cardiovascular medicine · 2026Review
- Initial Pre-Clinical Evaluation of the Augmented Ultra-Low Temperature Cryoablation Catheter for Ventricular Ablations.Journal of cardiovascular electrophysiology · 2026Article
- Ablation Methods and Catheter Settings for Ventricular Tachycardia Ablation: A Bench to Bedside Review: Part 2.Arrhythmia & electrophysiology review · 2026Review
- The New Ice Age in Electrophysiology: Ultra-Low-Temperature Cryoablation for Ventricular Tachycardia.Current cardiology reports · 2025Review
- Advances in Clinical Cardiology 2024: A Summary of Key Clinical Trials.Advances in therapy · 2025Review
- Epicardial ventricular arrhythmia ablation: a clinical consensus statement of the European Heart Rhythm Association of the European Society of Cardiology and the Heart Rhythm Society, the Asian Pacific Heart Rhythm Society, the Latin American Heart Rhythm Society, and the Canadian Heart Rhythm Society.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Article
- Targeting Ventricular Arrhythmias in Non-Ischemic Patients: Advances in Diagnosis and Treatment.Diagnostics (Basel, Switzerland) · 2025Review
- Pre-ablation and Post-ablation Factors Influencing the Prognosis of Patients with Electrical Storm Treated by Radiofrequency Catheter Ablation: An Update.Reviews in cardiovascular medicine · 2024Review
- Bipolar radiofrequency ablation of refractory ventricular arrhythmias: results from a multicentre network.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024Article
- Approaching Ventricular Tachycardia Ablation in 2024: An Update on Mapping and Ablation Strategies, Timing, and Future Directions.Journal of clinical medicine · 2024Review
- Letter from the Editor in Chief.The Journal of innovations in cardiac rhythm management · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 7 countries.
Funding
Abstract
aimsThe ultra-low-temperature cryoablation (ULTC) ablation system using -196°C N2 cryogen has been reported to create lesions with freeze duration-dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). METHODS AND
resultsThis prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1-9) to 0, IQR (0-2).
conclusionIn this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. CLINICAL
trial registrationNCT04893317.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.